Second-line treatment options in non-small cell lung cancer: A comparison of cytotoxic agents and targeted therapies

Filippo De Marinis, Stefano De Santis, Luigi De Petris

Research output: Contribution to journalArticle

Abstract

Current options for the second-line treatment of non-small cell lung cancer (NSCLC) include cytotoxic drugs, such as docetaxel and pemetrexed, and targeted therapies. Docetaxel was approved in the United States and Europe in 2000 after two phase III trials showed drug superiority versus best supportive care alone and versus alternative single-agent chemotherapy. Pemetrexed was approved in the United States and Europe in 2004 after a phase III trial showed that, compared with docetaxel, it had comparable activity (median survival time of approximately 8 months in both arms) and a more favorable toxicity profile: grade 3-4 neutropenia was observed in 5.3% versus 40.2% of patients in the pemetrexed and docetaxel arms, respectively, while febrile neutropenia was observed in 1.9% versus 12.7% of patients, respectively. In the United States, gefitinib and erlotinib have also been approved for the treatment of recurrent NSCLC (in 2003 and 2004, respectively), while in Europe the registration of these agents is currently under evaluation. This review focuses on the use of docetaxel and pemetrexed for the second-line treatment of NSCLC and compares these drugs with targeted therapies, highlighting the latest developments in pharmacogenomics that might lead to a more tailored approach to treatment.

Original languageEnglish
JournalSeminars in Oncology
Volume33
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Feb 2006

Fingerprint

docetaxel
Pemetrexed
Cytotoxins
Non-Small Cell Lung Carcinoma
Therapeutics
Pharmaceutical Preparations
Febrile Neutropenia
Pharmacogenetics
Neutropenia
Drug Therapy
Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Second-line treatment options in non-small cell lung cancer : A comparison of cytotoxic agents and targeted therapies. / De Marinis, Filippo; De Santis, Stefano; De Petris, Luigi.

In: Seminars in Oncology, Vol. 33, No. SUPPL. 1, 02.2006.

Research output: Contribution to journalArticle

@article{539ad9366e2a420a89163459a66b87cb,
title = "Second-line treatment options in non-small cell lung cancer: A comparison of cytotoxic agents and targeted therapies",
abstract = "Current options for the second-line treatment of non-small cell lung cancer (NSCLC) include cytotoxic drugs, such as docetaxel and pemetrexed, and targeted therapies. Docetaxel was approved in the United States and Europe in 2000 after two phase III trials showed drug superiority versus best supportive care alone and versus alternative single-agent chemotherapy. Pemetrexed was approved in the United States and Europe in 2004 after a phase III trial showed that, compared with docetaxel, it had comparable activity (median survival time of approximately 8 months in both arms) and a more favorable toxicity profile: grade 3-4 neutropenia was observed in 5.3{\%} versus 40.2{\%} of patients in the pemetrexed and docetaxel arms, respectively, while febrile neutropenia was observed in 1.9{\%} versus 12.7{\%} of patients, respectively. In the United States, gefitinib and erlotinib have also been approved for the treatment of recurrent NSCLC (in 2003 and 2004, respectively), while in Europe the registration of these agents is currently under evaluation. This review focuses on the use of docetaxel and pemetrexed for the second-line treatment of NSCLC and compares these drugs with targeted therapies, highlighting the latest developments in pharmacogenomics that might lead to a more tailored approach to treatment.",
author = "{De Marinis}, Filippo and {De Santis}, Stefano and {De Petris}, Luigi",
year = "2006",
month = "2",
doi = "10.1053/j.seminoncol.2005.12.004",
language = "English",
volume = "33",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Second-line treatment options in non-small cell lung cancer

T2 - A comparison of cytotoxic agents and targeted therapies

AU - De Marinis, Filippo

AU - De Santis, Stefano

AU - De Petris, Luigi

PY - 2006/2

Y1 - 2006/2

N2 - Current options for the second-line treatment of non-small cell lung cancer (NSCLC) include cytotoxic drugs, such as docetaxel and pemetrexed, and targeted therapies. Docetaxel was approved in the United States and Europe in 2000 after two phase III trials showed drug superiority versus best supportive care alone and versus alternative single-agent chemotherapy. Pemetrexed was approved in the United States and Europe in 2004 after a phase III trial showed that, compared with docetaxel, it had comparable activity (median survival time of approximately 8 months in both arms) and a more favorable toxicity profile: grade 3-4 neutropenia was observed in 5.3% versus 40.2% of patients in the pemetrexed and docetaxel arms, respectively, while febrile neutropenia was observed in 1.9% versus 12.7% of patients, respectively. In the United States, gefitinib and erlotinib have also been approved for the treatment of recurrent NSCLC (in 2003 and 2004, respectively), while in Europe the registration of these agents is currently under evaluation. This review focuses on the use of docetaxel and pemetrexed for the second-line treatment of NSCLC and compares these drugs with targeted therapies, highlighting the latest developments in pharmacogenomics that might lead to a more tailored approach to treatment.

AB - Current options for the second-line treatment of non-small cell lung cancer (NSCLC) include cytotoxic drugs, such as docetaxel and pemetrexed, and targeted therapies. Docetaxel was approved in the United States and Europe in 2000 after two phase III trials showed drug superiority versus best supportive care alone and versus alternative single-agent chemotherapy. Pemetrexed was approved in the United States and Europe in 2004 after a phase III trial showed that, compared with docetaxel, it had comparable activity (median survival time of approximately 8 months in both arms) and a more favorable toxicity profile: grade 3-4 neutropenia was observed in 5.3% versus 40.2% of patients in the pemetrexed and docetaxel arms, respectively, while febrile neutropenia was observed in 1.9% versus 12.7% of patients, respectively. In the United States, gefitinib and erlotinib have also been approved for the treatment of recurrent NSCLC (in 2003 and 2004, respectively), while in Europe the registration of these agents is currently under evaluation. This review focuses on the use of docetaxel and pemetrexed for the second-line treatment of NSCLC and compares these drugs with targeted therapies, highlighting the latest developments in pharmacogenomics that might lead to a more tailored approach to treatment.

UR - http://www.scopus.com/inward/record.url?scp=32044461557&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32044461557&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2005.12.004

DO - 10.1053/j.seminoncol.2005.12.004

M3 - Article

C2 - 16472705

AN - SCOPUS:32044461557

VL - 33

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - SUPPL. 1

ER -